There is already a targeted treatment for this disease. Gleevec, probably the most remarkable anti-cancer drug of the past decade, disables the protein encoded by another fused gene, BCR-ABL.

ABL will now undergo flight tests in which the aircraft will fire its high-energy laser, first into an onboard calorimeter, then through its beam control/fire control system.

When the activation tests are complete, ground firings of the laser will occur, followed by flight tests of the entire ABL weapon system.